2Seventy Bio company information, Employees & Contact Information

Pharmaceutical research and development pipeline Bristol Myers Squibb

Transparency & reporting Bristol Myers Squibb

Doctorx Unscripted Bold Conversations about Patient-Driven Science Bristol Myers Squibb

Business development leadership team Bristol Myers Squibb

The Bristol Myers Squibb Foundation Bristol Myers Squibb

Privacy notice center Bristol Myers Squibb

Clinical trials & studies Bristol Myers Squibb

Independent research Bristol Myers Squibb

Empowering patients with clarity & confidence through UPL program Bristol Myers Squibb

Worldwide locations Bristol Myers Squibb

Global Inclusion & Diversity Bristol Myers Squibb

Become a business supplier Bristol Myers Squibb

Areas of interest Bristol Myers Squibb

Our science Bristol Myers Squibb

Annual reports Bristol Myers Squibb

Our research in neuroscience Bristol Myers Squibb

Our impact Bristol Myers Squibb

About us Bristol Myers Squibb

People and business resource groups Bristol Myers Squibb

Muscarinic acetylcholine receptors fact sheet Bristol Myers Squibb

2025 Annual Meeting of Shareholders Bristol Myers Squibb

Working at BMS Bristol Myers Squibb

Research and development center Cambridge, Massachusetts Bristol Myers Squibb

Science Firsthand: Predicting new possibilities in drug discovery Bristol Myers Squibb

Women innovators in AI transforming patient care Bristol Myers Squibb

Commitment to safety and patients: Risk evaluation and mitigation strategies (REMS) Bristol Myers Squibb

A global journey through BMS’ R&D hubs Bristol Myers Squibb

Looking to the Future of Cell Therapy Bristol Myers Squibb

Leveraging AI to enhance workplace innovation & efficiency Bristol Myers Squibb

FDA Granted Breakthrough Therapy Designation for Treating NSCLC – BMS Oncodaily

(apixaban) Direct-to-Patient Program, Announces New BMS Patient Connect Platform Offering Sotyktu Business Wire

Unusual Liposome Image During Drug Research and Development Bristol Myers Squibb

Bristol Myers Squibb Announces Phase 3 EXCALIBER-RRMM Study Evaluating Iberdomide in Combination with Standard Therapies Demonstrated a Significant Improvement in Minimal Residual Disease Negativity Rates in Relapsed or Refractory Multiple M Business Wire

Bristol-Myers Squibb (BMY): Company Profile, Stock Price, News, Rankings Fortune

Bristol Myers Squibb Reports First Quarter Financial Results for 2025 Business Wire

Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader at EHA 2025 Business Wire

Bristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM Trial Business Wire

Continuing Innovations on TYK2 Inhibition Bristol Myers Squibb

Finding powerful healing through the support of Light The Night event Bristol Myers Squibb

Lynelle B. Hoch Bristol Myers Squibb

Our technologies Bristol Myers Squibb

Research on the Tumor Microenvironment Bristol Myers Squibb

Advances in Hematology with patient-centric approach Bristol Myers Squibb

Exploring New Approaches to Multiple Myeloma Treatment Bristol Myers Squibb

Featured Researcher: Michael (Mike) Ellis Bristol Myers Squibb

How BMS employees champion STEM education & diversity Bristol Myers Squibb

Opening Diverse Young Minds for STEM Careers in Pharma Bristol Myers Squibb

Bridging health disparities and transforming lives Bristol Myers Squibb

AI-driven protein degradation research reshaping drug discovery Bristol Myers Squibb

Meet Greg Meyers: Chief Digital & Technology Officer Bristol Myers Squibb

Milestone Chemotherapy Infusion For Cancer Patient in Lesotho Bristol Myers Squibb

Advancing Research for Treatment of Genitourinary Cancers Bristol Myers Squibb

U.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults Bristol Myers Squibb

Survivorship Today: Cancer survivor stories Bristol Myers Squibb

Our research in immunology Bristol Myers Squibb

U.S. FDA Approves Bristol Myers Squibb’s Breyanzi ® as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Bristol Myers Squibb

C2C4C: A decade-long quest for cancer cure Bristol Myers Squibb

U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy Bristol Myers Squibb

REMS patient companion app enables faster, easier surveys Bristol Myers Squibb

U.S. Food and Drug Administration Approves First LAG-3-Blocking Antibody Combination, Opdualag™ (nivolumab and relatlimab-rmbw), as Treatment for Patients with Unresectable or Metastatic Melanoma Bristol Myers Squibb

U.S. Food and Drug Administration Approves Camzyos™ (mavacamten) for the Treatment of Adults With Symptomatic New York Heart Association Class II-III Obstructive Hypertrophic Cardiomyopathy (HCM) to Improve Functional Capacity and Symptoms Bristol Myers Squibb

The future of diversity in clinical trials Bristol Myers Squibb

U.S. FDA Approves Bristol Myers Squibb’s Reblozyl® (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions Bristol Myers Squibb

Advancing lupus research to address unmet needs Bristol Myers Squibb

Chris Boerner, Board Chair and Chief Executive Officer Bristol Myers Squibb

Bristol Myers Squibb and Ted Danson Empower Those with Plaque Psoriasis to Take Action in “SO, Have You Found It?” Campaign Bristol Myers Squibb

Fulfilling our Role in Diversifying Clinical Trials Bristol Myers Squibb

Diversity in clinical trials is a scientific imperative Bristol Myers Squibb

Innovative R&D Labs in Kendall Square Bristol Myers Squibb

Protein Crystallization Experiment in Space for Improved Patient Care Bristol Myers Squibb

Advancing Our Breast Cancer Research Bristol Myers Squibb

Global Supply Chain Management During the COVID-19 Pandemic and Beyond Bristol Myers Squibb

U.S. Food and Drug Administration Approves Sotyktu™ (deucravacitinib), Oral Treatment for Adults with Moderate-to-Severe Plaque Psoriasis Bristol Myers Squibb

Igniting the Tumor Microenvironment to Fight Cancer Bristol Myers Squibb

Basketball Legend Kareem Abdul-Jabbar Joins No Time to Wait Campaign to Raise Awareness of Atrial Fibrillation (AFib) and its Symptoms Bristol Myers Squibb

U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel), a New CAR T Cell Therapy for Adults with Relapsed or Refractory Large B-cell Lymphoma Bristol Myers Squibb

Professional Service Automation Software for IT Professionals | Kaseya BMS Kaseya

U.S. Food and Drug Administration Approves Bristol Myers Squibb’s and bluebird bio’s Abecma (idecabtagene vicleucel), the First Anti-BCMA CAR T Cell Therapy for Relapsed or Refractory Multiple Myeloma Bristol Myers Squibb

Evolving Needs of People with Beta Thalassemia Bristol Myers Squibb

Bristol Myers Squibb Presents Positive Data from Two Pivotal Phase 3 Psoriasis Studies Demonstrating Superiority of Deucravacitinib Compared to Placebo and Otezla® (apremilast) Bristol Myers Squibb

Construction of CAR T facility in Leiden has started Bristol Myers Squibb

Hacking R&D: The Role of Artificial Intelligence Bristol Myers Squibb

Shareholder services Bristol Myers Squibb

Bristol Myers Squibb Releases 2023 Environmental, Social and Governance Report Demonstrating Progress and Setting New Long-Term Goals CSRwire

William Blair and BDA advise BMS on sale of its Couvet, Switzerland facility to WuXi AppTec BDA Partners